MyLungCancerTeam

Entrectinib (Rozlytrek) is a targeted therapy for ROS1-positive non-small cell lung cancer (NSCLC). It works by blocking ROS1 fusion proteins, slowing or stopping cancer growth. Common side effects include tiredness, constipation, taste changes, and swelling. For personal experiences, consider joining a support group or Show Full Answer

Entrectinib (Rozlytrek) is a targeted therapy for ROS1-positive non-small cell lung cancer (NSCLC). It works by blocking ROS1 fusion proteins, slowing or stopping cancer growth. Common side effects include tiredness, constipation, taste changes, and swelling. For personal experiences, consider joining a support group or forum like MyLungCancerTeam. Wishing you strength and healing!

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Rozlytrek (Entrectinib) for Lung Cancer | MyLungCancerTeam

Treatments for Lung Cancer | MyLungCancerTeam